ABIVAX (EPA:ABVX) | Finanzwire

PRESS RELEASE

published on 07/25/2025 at 08:00, 1 year 3 months ago

Abivax Announces Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)
Abivax announces full exercise of underwriters’ option to purchase additional ADSs, bringing gross proceeds of offering to $747.5M (€637.5M). Company to apply net proceeds to identified use of funds

Abivax Underwriters ADSs Offering Proceeds
BRIEF

published on 07/24/2025 at 14:45, 1 year 3 months ago

Abivax's $650M Public Offering of ADS

Biotechnology Abivax Capital Increase Public Offering Ads
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year 3 months ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax announces the trading resumption of its ordinary shares on Euronext Paris after a temporary halt for a public offering confirmation and pricing announcement

Euronext Paris Abivax Public Offering Clinical-stage Biotechnology Trading Resumption
PRESS RELEASE

published on 07/24/2025 at 14:40, 1 year 3 months ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares
Abivax announces pricing of $650M (€554M) public offering of American Depositary Shares to fund clinical development and working capital, with expected closing on July 28, 2025

Abivax Clinical Development Public Offering Pricing Closing
BRIEF

published on 07/24/2025 at 07:35, 1 year 3 months ago

Abivax Temporarily Halts Trading on Euronext Paris

Euronext Paris Biotechnology Abivax Trading Halt Public Offering
PRESS RELEASE

published on 07/24/2025 at 07:30, 1 year 3 months ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris due to public offering preparations

Euronext Paris Abivax Trading Halt Public Offering Clinical-stage Biotechnology
BRIEF

published on 07/23/2025 at 22:20, 1 year 3 months ago

Abivax Launches $400 Million Public Offering

Ulcerative Colitis Clinical Development Capital Market Abivax Public Offering Biotechnology Financing
PRESS RELEASE

published on 07/23/2025 at 22:15, 1 year 3 months ago

Abivax Announces Launch of Public Offering
Abivax announces launch of $400 million public offering to fund therapeutics for chronic inflammatory diseases. Underwritten by Leerink Partners, Piper Sandler, Guggenheim Securities, with LifeSci Capital, BTIG, Van Lanschot Kempen as managers

Biotechnology Financing Abivax Underwriters Public Offering
BRIEF

published on 07/22/2025 at 22:10, 1 year 3 months ago

Abivax Announces Positive Phase 3 Results for Obefazimod in Ulcerative Colitis

Abivax Obefazimod Ulcerative Colitis Phase 3 Trials MiR-124 Enhancer
PRESS RELEASE

published on 07/22/2025 at 22:05, 1 year 3 months ago

Abivax Announces Positive Phase 3 Results from Both ABTECT 8-Week Induction Trials Investigating Obefazimod, its First-in-Class Oral miR-124 Enhancer, in Moderate to Severely Active Ulcerative Colitis
Abivax announces positive Phase 3 results for obefazimod in ulcerative colitis trials, meeting key endpoints and demonstrating favorable tolerability. Conference call scheduled for more insights

Abivax Obefazimod Ulcerative Colitis Clinical Trials Phase 3 Results

Published on 10/30/2026 at 23:35, 2 days 7 hours ago

Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 2 days 7 hours ago

Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 2 days 9 hours ago

CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 2 days 11 hours ago

Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 2 days 15 hours ago

Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split

View all ACCESSWIRE

Published on 11/02/2026 at 06:00, 42 minutes ago

Wujiang Marks 90 Years Since Fei Xiaotong's Jiangcun Field Study
Published on 11/01/2026 at 10:35, 20 hours 7 minutes ago

Shenzhen Unveils APEC China 2026 Host-City Theme Song and Music Video
Published on 11/01/2026 at 05:00, 1 day 1 hour ago

2026 Yangtze River Culture Festival Opens in Yonglian Village, Zhangjiagang, Jiangsu
Published on 10/31/2026 at 16:35, 1 day 14 hours ago

SKYWORTH Solar Announces Global Launch of Solavita as a Smart Microgrid Brand
Published on 10/30/2026 at 22:49, 2 days 7 hours ago

EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE

View all EQS

Published on 10/30/2026 at 23:00, 2 days 7 hours ago

BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 20:42, 2 days 10 hours ago

TINC and PMV invest in Storm Group (B)
Published on 10/30/2026 at 18:00, 2 days 12 hours ago

2026 half-year earnings & third quarter revenue
Published on 10/30/2026 at 12:00, 2 days 18 hours ago

Capital increase through exercise of subscription rights
Published on 10/30/2026 at 08:45, 2 days 21 hours ago

Share buyback

View all LES ECHOS COMFI WIRE

News